Form 4: ResMed Director Peter C. Farrell Sells 2,000 Shares Under 10b5-1 Plan

ResMed director Peter C. Farrell sold 2,000 shares of common stock at $245.65 per share on December 4, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Peter C. Farrell, a director at ResMed Inc., sold 2,000 shares of ResMed common stock on December 4, 2024.
• The sale was executed at a price of $245.65 per share.
• This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on May 28, 2024.
• Following the transaction, Mr. Farrell beneficially owns 81,218 shares of ResMed common stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to a pre-planned stock sale by a director. It does not indicate any positive or negative sentiment about the company's performance.

Industry Context

This is a routine filing related to insider trading activity and is common for directors of publicly traded companies. The use of a 10b5-1 plan indicates the sale was pre-planned and not based on any non-public information.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among corporate insiders to avoid accusations of insider trading, aligning with standard practices in the industry.
• The sale of 2,000 shares is a relatively small transaction compared to the overall holdings of a director, and is not unusual for directors of companies of this size.

Stakeholder Impact

• The sale of shares by a director may have a minor impact on shareholder sentiment, but the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates

Keywords

ResMed, RMD, Peter C. Farrell, stock sale, Form 4, 10b5-1 plan, insider trading